AveXis Target of Unusually Large Options Trading (AVXS)

AveXis (NASDAQ:AVXS) was the target of unusually large options trading activity on Wednesday. Traders purchased 17,895 put options on the stock. This represents an increase of 3,430% compared to the typical daily volume of 507 put options.

In other news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $118.13, for a total value of $236,260.00. Following the transaction, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $826,910. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $119.50, for a total transaction of $1,792,500.00. Following the completion of the transaction, the insider now directly owns 1,767,766 shares in the company, valued at approximately $211,248,037. The disclosure for this sale can be found here. Insiders sold a total of 63,780 shares of company stock worth $7,808,578 over the last quarter. Corporate insiders own 18.60% of the company’s stock.

How to Become a New Pot Stock Millionaire

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AveXis by 57.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after purchasing an additional 453 shares during the last quarter. QS Investors LLC bought a new position in shares of AveXis during the 4th quarter valued at $156,000. Cubist Systematic Strategies LLC grew its holdings in shares of AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares during the last quarter. Vident Investment Advisory LLC bought a new position in shares of AveXis during the 3rd quarter valued at $245,000. Finally, Public Employees Retirement Association of Colorado bought a new position in shares of AveXis during the 4th quarter valued at $251,000. 82.23% of the stock is currently owned by institutional investors.



A number of brokerages have recently commented on AVXS. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating in a report on Wednesday. Chardan Capital lowered shares of AveXis from a “buy” rating to a “neutral” rating in a report on Friday, April 13th. Barclays lowered shares of AveXis from an “overweight” rating to an “equal weight” rating and set a $152.00 price target on the stock. in a report on Thursday, April 12th. UBS lowered shares of AveXis from a “buy” rating to a “neutral” rating in a report on Thursday, April 12th. Finally, Credit Suisse Group reissued a “neutral” rating and issued a $139.00 price target on shares of AveXis in a report on Wednesday, April 11th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company’s stock. AveXis has a consensus rating of “Hold” and an average price target of $123.90.

AVXS stock opened at $209.60 on Thursday. AveXis has a 52 week low of $65.54 and a 52 week high of $213.70.

AveXis (NASDAQ:AVXS) last released its earnings results on Tuesday, February 27th. The company reported ($2.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). equities research analysts forecast that AveXis will post -7.63 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “AveXis Target of Unusually Large Options Trading (AVXS)” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/04/19/avexis-target-of-unusually-large-options-trading-avxs.html.

About AveXis

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply